Markets

Top Ranked Momentum Stocks to Buy for February 25th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 25th:

Agilent Technologies, Inc. (A): This provider of application focused solutions to the life sciences, diagnostics and applied chemicals industries has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.7% over the last 60 days.

Agilent Technologies, Inc. Price and Consensus

Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote

Agilent Technologies' shares gained 6.5% over the last one month more than S&P 500's gain of 4.8%. The company possesses a Momentum Score of A.

Agilent Technologies, Inc. Price

Agilent Technologies, Inc. price | Agilent Technologies, Inc. Quote

Atlas Air Worldwide Holdings, Inc. (AAWW): This provider of outsourced aircraft and aviation operating services has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.8% over the last 60 days.

Atlas Air Worldwide Holdings Price and Consensus

Atlas Air Worldwide Holdings price-consensus-chart | Atlas Air Worldwide Holdings Quote

Atlas Air Worldwide's shares gained 14.8% over the last one month. The company possesses a Momentum Score of B.

Atlas Air Worldwide Holdings Price

Atlas Air Worldwide Holdings price | Atlas Air Worldwide Holdings Quote

Atlantic Capital Bancshares, Inc. (ACBI): This provider of commercial banking products and services has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.6% over the last 60 days.

Atlantic Capital Bancshares, Inc. Price and Consensus

Atlantic Capital Bancshares, Inc. price-consensus-chart | Atlantic Capital Bancshares, Inc. Quote

Atlantic Capital's shares gained 6.9% over the last one month. The company possesses a Momentum Score of B.

Atlantic Capital Bancshares, Inc. Price

Atlantic Capital Bancshares, Inc. price | Atlantic Capital Bancshares, Inc. Quote

Aduro BioTech, Inc. (ADRO): This immunotherapy company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.8% over the last 60 days.

Aduro Biotech, Inc. Price and Consensus

Aduro Biotech, Inc. price-consensus-chart | Aduro Biotech, Inc. Quote

Aduro BioTech's shares gained 54.9% over the last one month. The company possesses a Momentum Score of A.

Aduro Biotech, Inc. Price

Aduro Biotech, Inc. price | Aduro Biotech, Inc. Quote

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here .

The Could Be the Fastest Way to Grow Wealth in 2019

Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.

These companies are changing the world - and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.

Click here to see these breakthrough stocks now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report

Atlantic Capital Bancshares, Inc. (ACBI): Free Stock Analysis Report

Atlas Air Worldwide Holdings (AAWW): Free Stock Analysis Report

Agilent Technologies, Inc. (A): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ACBI KDNY A AAWW

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More